Busulfan-Fludarabine Versus Busulfan-Cyclophosphamide for Allogeneic Transplant in Acute Myeloid Leukemia: Long Term Analysis of GITMO AML-R2 Trial

Busulfan-Fludarabine Versus Busulfan-Cyclophosphamide for Allogeneic Transplant in Acute Myeloid Leukemia: Long Term Analysis of GITMO AML-R2 Trial | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Busulfan-Fludarabine Versus Busulfan-Cyclophosphamide for Allogeneic Transplant in Acute Myeloid Leukemia: Long Term Analysis of GITMO AML-R2 Trial Alessandro Rambaldi, Gianluca Cavallaro, Anna Grassi, Chiara Pavoni, and 28 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4595013/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 21 Aug, 2024 Read the published version in Blood Cancer Journal → Version 1 posted 8 You are reading this latest preprint version Abstract We report the long-term results of a randomized trial (GITMO, AML-R2), comparing 1:1 the combination of busulfan and cyclophosphamide (BuCy2, n= 125) and the combination of busulfan and fludarabine (BuFlu, n= 127) as conditioning regimen in acute myeloid leukemia patients (median age 51 years, range 40-65) undergoing allogeneic hematopoietic stem cell transplantation. With a median follow-up of 6 years, significantly better non-relapse mortality (NRM) was confirmed in BuFlu recipients, which is sustained up to 4 years after transplant (10% vs 20%, p= 0.0388). This difference was higher in patients older than 51 years (11 % in BuFlu vs 27% in BuCy2, p= 0.0262). The cumulative incidence of relapse, which was the first cause of death in the entire study population, did not differ between the two randomized arms. Similarly, the leukemia-free survival (LFS) and overall survival (OS) were not different in the two cohorts, even when stratifying patients per median age. Graft-and relapse free-survival (GRFS) in BuFlu arm vs the BuCy2 arm was 25% vs 20% at 4 years and 20% vs 17% at 10 years. Hence, the benefit gained by NRM reduction is not offsets by an increased relapse. Leukemia relapse remains a major concern, urging the development of new therapeutic approaches. Health sciences/Medical research/Clinical trial design/Randomized controlled trials Health sciences/Medical research/Clinical trial design/Clinical trials/Phase III trials Figures Figure 1 Figure 2 Figure 3 Figure 4 Introduction Acute myeloid leukemia (AML) currently represents the first indication of hematopoietic stem cell transplantation (HSCT) 1 , especially in intermediate and poor risk profile in first complete remission (CR) 2 . It represents the sole potentially curative treatment for relapsed/refractory disease 3 . For decades, the association between busulfan and cyclophosphamide (BuCy2) has been the standard of care conditioning regimen for HSCT in AML patients, showing favorable outcomes when compared to the combination of cyclophosphamide and total body irradiation (TBI) 4,5 . However, pivotal studies incorporating this regimen showed significant rates of non-relapse mortality (NRM) events, which make this therapy difficult to apply in patients older than 40 years old. Reduced-intensity conditioning regimens are associated with lower NRM, but this benefit could be offset by an increased incidence of relapse 6 . Therefore, new conditioning regimens were developed, to maintain antileukemic and myeloablative properties while reducing therapy-related toxicity, making it suitable also for older or comorbid AML patients. These are generally referred to as reduced toxicity myeloablative conditioning regimens. Among reduced toxicity regimens, the association of busulfan and fludarabine (BuFlu) represents a prototype 7 . Early experiences showed the efficacy of this combination in AML patients 8 , showing nonetheless conflicting data on disease relapse when compared to BuCy2 in non-randomized studies 9,10 . The AML-R2 trial was a phase 3 trial planned and conducted by the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) comparing busulfan-fludarabine (BuFlu) and busulfan-cyclophosphamide (BuCy2) as myeloablative conditioning regimens in acute myeloid leukemia (AML) patients undergoing allogeneic stem cell transplantation (Clinicaltrial.gov identifier: NCT01191957) 11 . The primary endpoint was 1-year non-relapse mortality (NRM), which proved significantly lower in BuFlu (7.9% vs. 17.2% in BuCy2 arm, p = 0.026). There was no difference between the two arms in terms of cumulative incidence of relapse (CIR), leukemia free survival (LFS), overall survival (OS) at 1 and 2 years after transplant. Grade III-IV acute graft versus host disease (GvHD) was significantly higher in BuCy2 group (12 patients [10%]) than BuFlu group (3 patients [2%]). Hereby, we present the long-term follow-up analysis of this clinical trial and provide a sub-analysis on patients older than 51 years. Methods Patients’ study population and trial design Details concerning eligibility criteria and study treatments were reported in the original publication 11 . Briefly, patients were eligible if they were aged 40–65 years, had an AML in first or second CR, had an Eastern Cooperative Oncology Group (ECOG) less than 3, had a sibling or matched unrelated donor with a molecular high-resolution typing of the HLA-A, B, C and DRB1 [One antigen/allele disparity (class I) or one allele disparity (class II, DRB1) was acceptable]. Key exclusion criteria were represented by AML with t(15;17) or PML/RARα positive acute promyelocytic leukemia, or AML with t(8;21)(q22;q22), inv( 16 ) or t(16;16)(p13;q22) without additional adverse cytogenetic abnormalities; a previous HSCT; presence of comorbidities that would preclude the HSCT or the ability to provide truly informed consent; an active neoplasm or history of malignancies within 2 years before enrolment. both treatment groups received the same intravenous myeloablative dose of busulfan, 0.8 mg/kg four times per day for four consecutive days. In BuCy2 group, busulfan was combined with a standard dose of cyclophosphamide, 60 mg/kg per day for two consecutive days (on days − 4 and − 3, total dose 120 mg/kg); in BuFlu group, cyclophosphamide was replaced by fludarabine 40 mg/sqm per day for four consecutive days (from day − 6 through day − 3, total dose 160 mg/sqm). Transplant was performed on day 0, with patients receiving either bone marrow or granulocyte-colony stimulating agent (G-CSF) mobilized peripheral blood stem cells (PBSC). Graft-versus-host-disease (GvHD) prophylaxis was based on cyclosporine-A (1.5 mg/kg twice per day, starting from day − 1) and methotrexate (15 mg/sqm on day 1, 10 mg/sqm on days 3, 6, 11); in case of unrelated donors, anti-Thymocyte Globulin (ATG) was given at a total dose of 5 mg/kg (or 7.5 mg/kg in case of HLA acceptable disparity). For this long-term analysis, upon obtaining a written informed consent, we evaluated the long-term NRM, LFS, CIR, OS, chronic GvHD and relapse-free survival (GRFS) and the incidence of cGvHD of any grade. We also searched for long-term adverse events, especially second neoplasms, which were defined as invasive cancers, excluding basal cell and in situ skin cancers 12 . Outcomes were evaluated from the day of transplant in the intention-to-treat population, for the entire study population and then further stratified according to the median age (51 years). The choice of analyzing this subpopulation is based on the paucity of data from randomized trial concerning the use myeloablative conditioning regimen for AML transplantation in older adults. The study was approved by the Bergamo ethics committee. Statistical analysis All the clinical outcomes were calculated from transplant to the first event or the last follow- up. Non-relapse mortality (NRM) was defined as death from any cause not subsequent to relapse. Overall survival (OS) was defined as the time from transplant to death from any cause. Leukemia-free survival (LFS) was defined as the time from transplant to disease relapse or death from any cause, whichever came first. Chronic GVHD-free and leukemia-free survival (GLFS) was defined as the time from transplant to disease relapse or chronic GVHD or death from any cause, whichever came first. Disease relapse was defined as hematological relapse (blast counts > 5% in bone marrow). NRM, cumulative incidence of relapse (CIR) and chronic GvHD incidence were estimated using cumulative incidence function, considering relapse and death as a competing event for NRM and other incidence, respectively; the Gray’s non-parametric test was used to assess group differences. OS, LFS and GLFS were estimated using the Kaplan-Meier method and the log-rank test was applied to test differences between groups. Univariate analysis was performed by fitting Fine and Gray models for cumulative incidences and Cox models for survival outcomes. Hazard ratio with 95% confidence intervals were reported. A significance level of 0.05 was fixed. All the analysis were performed with R software (version 4.0.0). Results From January 3, 2008, to December 20, 2012, 252 AML patients with a median age of 51 years, were randomized 1:1 to BuCy2 (n = 125) or BuFlu (n = 127). Treatment was delivered in 121 patients in BuCy2 arm and 124 patients in BuFlu arm; baseline patients’ characteristics are reported in Table 1 . The median follow-up for the study population was 6 years (range 0.03-13). The NRM for the entire study population remained significantly different up to 4 years after transplant (10% in BuFlu arm vs 20% in BuCy2 arm, p = 0.0388). The NRM was not different for patients younger than 51 years (10% in BuFlu vs 14% in BuCy2, p = NS), but it was remarkably significant in patients older than 51 years (11% in BuFlu vs 27% in BuCy2, p = 0.0262) (Fig. 1 ). Table 1 Baseline patients’ and transplant characteristics Characteristics All n = 252 (%) BuFlu n = 127 (%) BuCy2 n = 125 (%) p Age, years median (range) 50.8 (38–65) 51.1 (38–65) 50.5 (39–65) ns < 51 128 (50.8) 62 (48.8) 66 (52.8) ns ≥ 51 124 (49.2) 65 (51.2) 59 (47.2) ns Sex female 113 (44.8) 57 (44.9) 56 (44.8) ns male 139 (55.2) 70 (55.1) 69 (55.2) ns AML type de novo 205 (81.3) 103 (81.1) 102 (81.6) ns secondary 46 (18.3) 24 (18.9) 22 (17.6) ns unknown 1 (0.4) 0 1 (0.8) ns Disease status at alloSCT 1° CR 213 (84.5) 108 (85.0) 105 (84) ns ≥ 2° CR 37 (14.7) 18 (14.2) 19 (15.2) ns unknown 2 (0.8) 1 (0.8) 1 (0.8) ns ELN risk good 27 (10.7) 13 (10.2) 14 (11.2) ns intermediate-1 123 (48.8) 62 (48.8) 61 (48.8) ns intermediate-2 40 (15.9) 17 (13.4) 23 (18.4) ns adverse 55 (21.8) 32 (25.2) 23 (18.4) ns unknown 7 (2.8) 3 (2.4) 4 (3.2) ns Donor type related 114 (45.2) 58 (45.7) 56 (44.8) ns unrelated 138 (54.8) 69 (54.3) 69 (55.2) ns Graft source bone marrow 77 (30.6) 36 (28.3) 41 (32.8) ns peripheral blood 168 (66.7) 88 (69.3) 80 (64.0) ns unknown 7 (2.8) 3 (2.4) 4 (3.2) ns Donor-recipient sex pair female to male 42 (16.7) 23 (18.1) 19 (15.2) ns others 209 (82.9) 104 (81.9) 105 (84.0) ns unknown 1 (0.4) 0 1 (0.8) ns Recipient/donor CMV serology negative/negative 20 (8.0) 12 (9.5) 8 (6.4) ns negative/positive 16 (6.3) 6 (4.7) 10 (8.0) ns positive/negative 68 (27.0) 37 (29.1) 31 (24.8) ns positive /positive 144 (57.1) 69 (54.3) 75 (60.0) ns unknown 4 (1.6) 3 (2.4) 1 (0.8) ns Moreover, patients older than 51 years in the BuCy2 arm, had an incidence of non-relapse death of 23% in the first year after transplant, with infections being the first cause of death (14.3%), even more than disease relapse (10.7%); on the contrary, in this population, non-relapse death in BuFlu arm was 9.5% in the first year. Death events in the first year after transplant for patients older than 51 years are summarized in Fig. 2 . Patients older than 51 years receiving BuFlu also experienced fewer organ-specific toxicities, which are early-onset adverse events strictly related to the conditioning regimen itself. As shown in Table 2 , patients receiving BuCy2 had a higher number of any grade toxic event, especially grade 2–3 (27 events in BuCy arms vs 17 events in the BuFlu arm). Table 2 Conditioning-related toxicities in the first month after transplant in patients older than 51 years BuCy2 (n = 58) BuFlu (n = 63) Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3 Mucosa 4 (7%) 13 (22%) 1 (2%) 7 (11%) 12 (19%) 1 (2%) Liver 4 (7%) 3 (5%) 0 2 (3%) 1 (2%) 0 Gut 6 (10%) 2 (3%) 1 (2%) 2 (3%) 1 (2%) 0 Bladder 0 3 (5%) 1 (2%) 0 0 0 Heart 0 1 (2%) 1 (2%) 0 0 0 Kidney 2 (3%) 0 0 1 (2%) 0 0 CNS 0 1 (2%) 0 0 1 (2%) 0 Lung 1 (2%) 0 0 0 1 (2%) 0 We observed 46 relapses in the BuCy2 arm and 53 in the BuFlu arm, with most relapses diagnosed in the first 2 years after transplant; 8% of relapses occurred later than 5 after transplant (3 in the BuCy2 arm, 5 in the BuFlu arm). The CIR was not statistically different in both arms (39% vs 37% in BuFlu vs. BuCy2 arm, Fig. 3 ). Similarly, we did not observe any difference in LFS (45% vs 38% in BuFlu and BuCy2 arms, respectively) and OS (45% in both arms); curves are shown in Fig. 4 . We also did not observe a difference in cumulative incidence of moderate/severe cGvHD (15% in the BuFlu arm vs 22% in the BuCy2 arm) and GRFS in the BuFlu arm vs the BuCy2 arm (25% vs 20% at 4 years; 20% vs 17% at 10 years, respectively). During the entire available follow-up, we observed a total of 137 deaths, 66 in BuCy2 arm and 71 in the BuFlu arm. Disease relapse was the main cause of death, occurring in 88 patients (37 in the BuCy2 arm vs 51 in the BuFlu arm), while non-relapse events leading to death occurred in 49 patients (29 in Bucy2 arm vs 20 in BuFlu arm). In the original trial, NRM events were 36, 23 in BuCy2 arm and 13 in BuFlu arm (p = 0.060). Long-term analysis showed 13 new NRM events, 5 in BuCy2 arm (2 for second neoplasm, 2 for infection, 1 for other unspecified reason) and 8 in BuFlu arm (5 for second neoplasm, 2 for infection, 1 for cardiovascular disease). Among the 13 deceased patients, 6 had a concomitant moderate/severe cGvHD. Table 3 summarizes all death events occurring along the entire available follow-up. Table 3 Death events along the entire available post-transplant follow-up 13 years post transplant BuCy2 (n = 125) BuFlu (n = 127) TOTAL MORTALITY 66 (52.8%) 71 (55.9%) Relapse death 37 (29.6%) 51 (40.2%) Non relapse death 29 (23.2%) 20 (15.7%) Infection 16 (55%) 8 (40%) Pneumonia Bacterial / Viral / Fungal / Unknown 9 3 / 1 / 1 / 3 6 1 / 2 / 1 / 2 Encephalitis 2 - Unspecified infection 5 2 Acute GvHD 5 (17%) 3 (15%) Second neoplasms 2 (7%) 5 (25%) Cardiac toxicity 2 (7%) 2 (10%) Gastrointestinal toxicity 1 (3%) - Hemorrhage 1 (3%) 1 (5%) Other 2 (7%) 1 (5%) We detected a total of 19 second neoplasms, 6 in BuCy2 arm and 13 in BuFlu arm; in 7 cases, the second tumor was the cause of death (n = 5 in BuFlu arm, n = 2 in BuCy2 arm). Discussion The AML-R2 study planned and conducted by the GITMO group showed a reduction in NRM in BuFlu compared to the BuCy2 arm, with no detrimental effects on disease relapse. This long-term analysis was aimed to confirm and further evaluate these findings throughout the available follow-up. We showed that the benefit of NRM reduction is sustained up to 4 years after transplant and the incidence of late relapses does not offset this advantage. Moreover, NRM continues to be halved in BuFlu arm, as it was initially hypothesized and proved in the clinical trial 1 year after the transplant. NRM proved lower in BuFlu arm even 10 years after transplant but, due to the occurrence of late non-relapse death in BuFlu arm, (infections and second neoplasms above all) the statistical significance is lost. Our data are in line with the analysis led by Fasslrinner et al., who analyzed the long-term outcomes of the randomized trial comparing two TBI-containing conditioning regimens in HSCT for AML, and showed that NRM at 10 years was not significantly different between the two study arms 13 . Indeed, many registry analyses with follow-up close to 10 years showed that patients undergoing HSCT have an increased risk of death compared to the general age-matched population for the sole reason of having received an HSCT, independently of the type of conditioning regimen and the disease for which the patient was transplanted 14 . The performed sub-analysis on patients older than 51 showed that the global benefit of BuFlu is due to NRM reduction in this specific population. Randomized data on myeloablative conditioning in patients above 51 years are rather sparse. Indeed, most of the available clinical data on myeloablative conditioning come from non-randomized studies in younger patients. Our analysis shows the feasibility of the myeloablative BuFlu regimen even in adults older than 51, with a NRM similar to younger patients and an acceptable safety profile. Our results also confirm that the myeloablative BuFlu program allows an optimal balance between anti-leukemic activity and toxicity 15 , with NRM comparable to those reported by recently published randomized trials comparing reduced intensity conditioning regimens 16,17 . A recent retrospective analysis of the Acute Leukemia Working Party of the European Society of Bone Marrow Transplant (EBMT) compared outcomes of a myeloablative combination of treosulfan and fludarabine (FT14) with BuFlu in patients with AML stratified per age older or younger than 55 years. With the limitation of a retrospective analysis and a relatively short follow-up, the FT14 conditioning was associated with a greater incidence of relapse and shorter LFS in patients younger than 55, while all the other outcomes were similar in patients older than 55. Limiting the analysis on patients receiving BuFlu, 2-year NRM was 7.7% and CIR was 27.5% 18 . Another recent publication of the Acute Leukemia Working Party of the EBMT retrospectively compared BuFlu with the myeloablative regimen based on TBI 12 Gy and fludarabine showing no difference between these two conditioning regimens, with a 2-year NRM and CIR in BuFlu arm of 10.9% and 29.4%, respectively 19 . Collectively, these findings from an International Registry demonstrate that real-life outcomes with BuFlu are basically superimposable to the ones observed in the clinical trial. A very recent randomized phase 3 trial from the Chinese group compared BuFlu and BuCy2 in the haploidentical setting. The 1-year NRM was 7.2% in BuFlu vs 14.1% in BuCy2, whereas the 5-year relapse incidence was 17.9% and 14.2% respectively. This study showed that outcomes with BuFlu are independent of the donor type and the subsequently adopted GvHD prophylaxis. Moreover, authors found a reduced incidence of grade 3 regimen-related toxicities (0% in BuFlu vs 9% in BuCy2), thus confirming that BuFlu is less toxic when compared to BuCy2, even in patients receiving post-transplant cyclophosphamide 20 . The long-term analysis of the AML-R2 trial showed that disease relapse nearly reaches 40% in both arms, with most relapses occurring within the first two years, in line with other reports 13,21 . This finding allows some considerations: first, the prolonged reduction in NRM is not offset by increased disease relapse and this is sustained even at a very long follow-up. In addition, disease relapse remains the leading cause of death in both arms and up to 8% of relapses occur later than 5 years after transplant, meaning that the treating physician should always be aware of the risk of the relapse, even at a very long follow-up, and in case of suspect, disease relapse must be thoroughly investigated. Finally, the risk definition according to the ELN classification was not associated with a major impact on late relapses. It has to be noted that, when the trial was conducted, post-transplant therapies (e.g., FLT3 inhibitors) were not available and this might have had a role in the high incidence of relapse we observed in both arms. Innovative post-transplant therapies are urgently needed. We observed a non-significant increase in relapse death in the BuFlu arm (53 relapses with 51 deaths) with regards to the BuCy2 arm (46 relapses and 39 deaths). This finding was already outlined in the original clinical trial publication and potentially linked to a deeper immunosuppressive microenvironment. However, the number of relapses does not allow us to draw a definitive conclusion, and mechanisms underlying late relapses are probably much more complex and likely unrelated to the conditioning regimen. Nonetheless, most patients who relapsed either after BuFlu or BuCy2, unfortunately died. It is therefore confirmed that the probability of prolonged leukemia control when transplant fails after myeloablative conditioning remains very limited. The combination of late non-relapse and relapse-associated deaths in the BuFlu arm explains the absence of any meaningful difference in the OS observed in the two randomized arms. Concerning long-term toxicities, we focused on second neoplasms, whose incidence was 8%. The incidence of secondary neoplasms in the entire cohort is in line with data showing a progressive rise when an appropriate long-term follow-up analysis is conducted 22 . We observed a slight increase in second neoplasm incidence in BuFlu arm, although the absolute number of events is too low to reach a statistical significance. The deeper immunosuppressive activity of fludarabine could be also related to this late development of a second neoplasm. Nonetheless, cancerogenesis is a complex process in which many other transplant-related features could play a role, mainly cGvHD with all the related immunosuppressive therapy. In addition, retrospective studies did not find any difference between RIC and MAC regimens with the development 23,24 of secondary neoplasms, further suggesting that the type of conditioning on second neoplasms is not straightforward. This long-term analysis has some limitations. First, these long-term follow-up data were collected retrospectively and were merged with data from the clinical trial, which were collected prospectively. Second, this long-term analysis was not pre-planned, so information concerning long-term follow-up has been collected according to the local clinical practice of the participating centers. Finally, the clinical trial was not designed to identify differences according to the median age of the study population. Nonetheless, we confirmed a sustained reduction in NRM when the myeloablative BuFlu is used as a conditioning regimen in adult AML. Based on these long-term results from a randomized multicentre study, we believe that this preparative regimen should be considered as a standard of care conditioning regimen for AML patients undergoing HSCT, even in the haploidentical setting. The possibility to use this conditioning regimen can be extended to a selected group of AML patients older than 51 years, for whom a myeloablative regimen could provide a more active anti-leukemic effect 6,25 . For these patients, BuFlu is associated with a reduction in early conditioning-related organ toxicities. Since the low NRM has been confirmed after a long-term follow-up, this offers the possibility to plan effective innovative post-transplant therapies to tackle the risk of disease relapse, which remains the major unmet clinical need after transplantation. Declarations Competing interests Authors declare no competing interests. Acknowledgment This work was in part supported with grants by the Associazione Italiana per la Ricerca sul Cancro (AIRC) and the Associazione Italiana Lotta alla Leucemia (Sezione Paolo Belli, Bergamo, Italy). We thank all physicians and nursing staff of GITMO Centers for the clinical care of patients enrolled in this study, and the data manager for data acquisition. Authors’ Contribution Conception and design : Alessandro Rambaldi designed the clinical trial. Provision of study materials or patients : Gianluca Cavallaro, Anna Grassi, Maria Caterina Micò, Alessandro Busca, Irene Maria Cavattoni, Stella Santarone, Carlo Borghero, Attilio Olivieri, Giuseppe Milone, Patrizia Chiusolo, Pellegrino Musto, Riccardo Saccardi, Francesca Patriarca, Fabrizio Pane, Giorgia Saporiti, Paolo Rivela, Elisabetta Terruzzi, Raffaella Cerretti, Giuseppe Marotta, Angelo Michele Carella, Arnon Nagler, Domenico Russo, Paolo Corradini, Paolo Bernasconi, Anna Paola Iori, Luca Castagna, Nicola Mordini, Elena Oldani, Carmen Di Grazia, Andrea Bacigalupo, Alessandro Rambaldi Collection and assembly of data : Gianluca Cavallaro, Anna Grassi, Chiara Pavoni Data analysis and interpretation : Chiara Pavoni, Gianluca Cavallaro, Anna Grassi, Alessandro Rambaldi Manuscript writing : All authors Final approval of manuscript : All authors Accountable for all aspects of the work : All authors References D’Souza A, Fretham C, Lee SJ, et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant . 2020;26(8):e177-e182 Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood . 2016;127(1):62-70 Heinicke T, Krahl R, Kahl C, et al. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. Ann Hematol . 2021;100(9):2387-2398 Nagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: Comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus cy as conditioning regimen-A report from the acute leukemia workin. J Clin Oncol . 2013;31(28):3549-3556 Copelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood . 2013;122(24):3863-3870 Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol . 2017;35(11):1154-1161 De Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood . 2004;104(3):857-864 Andersson BS, de Lima M, Thall PF, et al. Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS. Biol Blood Marrow Transplant . 2008;14(6):672-684 Chae YS, Sohn SK, Kim JG, et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: Comparison with BuCy2. Bone Marrow Transplant . 2007;40(6):541-547 Bredeson CN, Zhang MJ, Agovi MA, et al. Outcomes following HSCT Using Fludarabine, Busulfan, and Thymoglobulin: A Matched Comparison to Allogeneic Transplants Conditioned with Busulfan and Cyclophosphamide. Biol Blood Marrow Transplant . 2008;14(9):993-1003 Rambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial. Lancet Oncol . 2015;16(15):1525-1536 Rizzo JD, Curtis RE, Sobocinski KA, et al. Solid cancers after allogeneic hematopoietic cell transplantation. 2009;113(5):1175-1183 Fasslrinner F, Schetelig J, Burchert A, et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase . Lancet Haematol . 2018;5(4):e161-e169 Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther . 2017;10(4):220-227 Liu H, Zhai X, Song Z, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: A prospective and multicen. J Hematol Oncol . 2013;6(1):1-9 Craddock C, Jackson A, Loke J, et al. Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol . 2021;39(7):768-778 Beelen DW, Trenschel R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 . Lancet Haematol . 2020;7(1):e28-e39 Gavriilaki E, Labopin M, Sakellari I, et al. Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia. Bone Marrow Transplant . 2022;(October 2021):1-7. Swoboda R, Labopin M, Giebel S, et al. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par. Bone Marrow Transplant . 2023;58(3):282-287 Ling Y, Xuan L, Xu N, et al. Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. J Clin Oncol 2023:1-12 Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol . 2011;29(16):2230-2239 Majhail NS, Brazauskas R, Douglas Rizzo J, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood . 2011;117(1):316-322 Ringdén O, Brazauskas R, Wang Z, et al. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant . 2014;20(11):1777-1784 Shimoni A, Shem-Tov N, Chetrit A, et al. Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; The incidence is not reduced. Leukemia . 2013;27(4):829-835 Scott BL, Pasquini MC, Fei M, et al. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial: Transplant Cell Ther . 2021;27(6):483.e1-483.e6. Additional Declarations There is NO conflict of interest to disclose. Cite Share Download PDF Status: Published Journal Publication published 21 Aug, 2024 Read the published version in Blood Cancer Journal → Version 1 posted Editorial decision: revise 05 Jul, 2024 Review # 1 received at journal 26 Jun, 2024 Reviewer # 1 agreed at journal 20 Jun, 2024 Reviewers invited by journal 19 Jun, 2024 Editor assigned by journal 19 Jun, 2024 Submission checks completed at journal 19 Jun, 2024 First submitted to journal 18 Jun, 2024 Unknown event 18 Jun, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4595013","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":316613715,"identity":"274fb07a-ed55-4a1e-b4e8-fb0a563e41d1","order_by":0,"name":"Alessandro Rambaldi","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABA0lEQVRIie2Qv0oDQRCHJwRyzYjthCPeK2wQFosUPspcc5VIIJDK4kTYdKkVi3uGELDeIJhm8QW2CkGsDyGcjTpK2tyZLpD9qt/AfMwfgEDgQGkDXLRMlG/LaGKBmxVqGbQSf1vRMXCD86fkxFuFWEHdmNPH57f58IZ60+56XX5WcJ1cyohVtVuh10z7+xc6N3GmY2QY9e3C1i/mQHvsUGpi1m3g73R2m9ffkrho4/FLlO7yo6wY0tkdqFpFOdT+xIhCqEgWS4tOg9J3OPYPU7kFr8YxZjBSiGw5262cuejJDzeDXjFZzstqIB8r3hcrCf+HlQWwewiiJPle/YFAIHAE/AABg1MK3xnUUgAAAABJRU5ErkJggg==","orcid":"","institution":"ASST Papa Giovanni XXIII","correspondingAuthor":true,"prefix":"","firstName":"Alessandro","middleName":"","lastName":"Rambaldi","suffix":""},{"id":316613716,"identity":"626f0a42-19b8-4bb9-af25-1c888db248cf","order_by":1,"name":"Gianluca Cavallaro","email":"","orcid":"","institution":"Department of Oncology and Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo","correspondingAuthor":false,"prefix":"","firstName":"Gianluca","middleName":"","lastName":"Cavallaro","suffix":""},{"id":316613717,"identity":"8dfb047b-897c-4eb6-bd08-fee8531ad0cc","order_by":2,"name":"Anna Grassi","email":"","orcid":"","institution":"Department of Oncology and Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo","correspondingAuthor":false,"prefix":"","firstName":"Anna","middleName":"","lastName":"Grassi","suffix":""},{"id":316613718,"identity":"b2dd1f91-a089-4c28-b3d6-4e4199f9b42c","order_by":3,"name":"Chiara Pavoni","email":"","orcid":"","institution":"Department of Oncology and Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo","correspondingAuthor":false,"prefix":"","firstName":"Chiara","middleName":"","lastName":"Pavoni","suffix":""},{"id":316613719,"identity":"1710a368-0793-440e-acd8-29f2ab7d1f9e","order_by":4,"name":"Maria Caterina Micò","email":"","orcid":"","institution":"Department of Oncology and Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo","correspondingAuthor":false,"prefix":"","firstName":"Maria","middleName":"Caterina","lastName":"Micò","suffix":""},{"id":316613720,"identity":"7144138c-77a6-4938-ab3d-8f494a24ee6e","order_by":5,"name":"Alessandro Busca","email":"","orcid":"","institution":"A.O.U. Citta’ della Salute, Torino","correspondingAuthor":false,"prefix":"","firstName":"Alessandro","middleName":"","lastName":"Busca","suffix":""},{"id":316613721,"identity":"64e2c738-7f6d-4e7e-830d-1d05149df717","order_by":6,"name":"Irene Cavattoni","email":"","orcid":"","institution":"Ospedale S. Maurizio","correspondingAuthor":false,"prefix":"","firstName":"Irene","middleName":"","lastName":"Cavattoni","suffix":""},{"id":316613722,"identity":"0410cd59-a82c-4b1e-a554-f7955341421d","order_by":7,"name":"Stella Santarone","email":"","orcid":"https://orcid.org/0000-0002-5037-0515","institution":"BMT Center Ospedale Civile","correspondingAuthor":false,"prefix":"","firstName":"Stella","middleName":"","lastName":"Santarone","suffix":""},{"id":316613723,"identity":"651c6b37-b3d7-4f78-a4bf-e5e2fb530f84","order_by":8,"name":"Carlo Borghero","email":"","orcid":"","institution":"Dipartimento di Ematologia, Ospedale San Bortolo, Vicenza","correspondingAuthor":false,"prefix":"","firstName":"Carlo","middleName":"","lastName":"Borghero","suffix":""},{"id":316613724,"identity":"b31873cc-266e-487a-8931-2e139bc8a6b3","order_by":9,"name":"Attilio Olivieri","email":"","orcid":"","institution":"Ospedali Riuniti di Ancona","correspondingAuthor":false,"prefix":"","firstName":"Attilio","middleName":"","lastName":"Olivieri","suffix":""},{"id":316613725,"identity":"53f51719-5bce-4a06-afba-4087c4bf49f8","order_by":10,"name":"Giuseppe Milone","email":"","orcid":"https://orcid.org/0000-0002-7840-4414","institution":"Ospedale Policlinico Vittorio Emanuele","correspondingAuthor":false,"prefix":"","firstName":"Giuseppe","middleName":"","lastName":"Milone","suffix":""},{"id":316613726,"identity":"934600d8-8e33-4e48-a6e4-cac290cb8ee7","order_by":11,"name":"Patrizia Chiusolo","email":"","orcid":"https://orcid.org/0000-0002-1355-1587","institution":"Fondazione Policlinico Universitario A. Gemelli","correspondingAuthor":false,"prefix":"","firstName":"Patrizia","middleName":"","lastName":"Chiusolo","suffix":""},{"id":316613727,"identity":"34f3fc07-0405-4bf4-bdd2-f059ea37ca7a","order_by":12,"name":"Pellegrino Musto","email":"","orcid":"https://orcid.org/0000-0003-3277-6594","institution":"\"Aldo Moro\" University School of Medicine; AOU Consorziale Policlinico","correspondingAuthor":false,"prefix":"","firstName":"Pellegrino","middleName":"","lastName":"Musto","suffix":""},{"id":316613728,"identity":"70315847-20a3-4761-9c98-62d8a33c73d1","order_by":13,"name":"Riccardo Saccardi","email":"","orcid":"","institution":"Azienda Ospedaliero Universitaria Careggi, Firenze","correspondingAuthor":false,"prefix":"","firstName":"Riccardo","middleName":"","lastName":"Saccardi","suffix":""},{"id":316613729,"identity":"7dfa0cf8-599f-481b-9fb2-507030bf2ab1","order_by":14,"name":"Francesca Patriarca","email":"","orcid":"","institution":"Azienda sanitaria Universitaria Integrata Friuli Centrale","correspondingAuthor":false,"prefix":"","firstName":"Francesca","middleName":"","lastName":"Patriarca","suffix":""},{"id":316613730,"identity":"e7ebdb7e-b839-4001-96ee-f573c13aa32d","order_by":15,"name":"Fabrizio Pane","email":"","orcid":"","institution":"CEINGE Biotecnologie Avanzate, Naples, Italy","correspondingAuthor":false,"prefix":"","firstName":"Fabrizio","middleName":"","lastName":"Pane","suffix":""},{"id":316613731,"identity":"482d0b12-524c-472a-8b40-9313264eb710","order_by":16,"name":"Giorgia Saporiti","email":"","orcid":"","institution":"Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano","correspondingAuthor":false,"prefix":"","firstName":"Giorgia","middleName":"","lastName":"Saporiti","suffix":""},{"id":316613732,"identity":"bbaca8b7-dd1b-49f9-88d5-ba08259942e3","order_by":17,"name":"Paolo Rivela","email":"","orcid":"","institution":"Division of Hematology, A.O. SS Antonio e Biagio and Cesare Arrigo, Alessandria","correspondingAuthor":false,"prefix":"","firstName":"Paolo","middleName":"","lastName":"Rivela","suffix":""},{"id":316613733,"identity":"70234d5b-1688-4b37-b4e3-a95a3c39746b","order_by":18,"name":"Elisabetta Terruzzi","email":"","orcid":"","institution":"Hematology Division, San Gerardo Hospital, Monza","correspondingAuthor":false,"prefix":"","firstName":"Elisabetta","middleName":"","lastName":"Terruzzi","suffix":""},{"id":316613734,"identity":"58cd56e9-45e6-4ac2-a0ae-d225b2031c94","order_by":19,"name":"Raffaella Cerretti","email":"","orcid":"https://orcid.org/0000-0003-3638-0650","institution":"Università Tor Vergata","correspondingAuthor":false,"prefix":"","firstName":"Raffaella","middleName":"","lastName":"Cerretti","suffix":""},{"id":316613735,"identity":"5a6587ab-ac48-4fef-b129-b619212f8cbf","order_by":20,"name":"Giuseppe Marotta","email":"","orcid":"","institution":"Azienda Ospedaliera Universitaria Senese, Siena","correspondingAuthor":false,"prefix":"","firstName":"Giuseppe","middleName":"","lastName":"Marotta","suffix":""},{"id":316613736,"identity":"a74ab657-e1a4-45d3-bb66-ac5b2c073cc1","order_by":21,"name":"Angelo Michele Carella","email":"","orcid":"","institution":"Ematologia e Centro Trapianto CSE, Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo","correspondingAuthor":false,"prefix":"","firstName":"Angelo","middleName":"Michele","lastName":"Carella","suffix":""},{"id":316613737,"identity":"58ceb594-839b-476d-bf7e-a189168f660f","order_by":22,"name":"Nagler Arnon","email":"","orcid":"","institution":"The Chaim Sheba Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Nagler","middleName":"","lastName":"Arnon","suffix":""},{"id":316613738,"identity":"3a4ae72f-54e8-4d58-92dd-3ecfeb664e17","order_by":23,"name":"Domenico Russo","email":"","orcid":"","institution":"Chair of Hematology, Bone Marrow Transplant Unit","correspondingAuthor":false,"prefix":"","firstName":"Domenico","middleName":"","lastName":"Russo","suffix":""},{"id":316613739,"identity":"5c9b10ac-6593-4b89-80c4-446d4bbc156d","order_by":24,"name":"Paolo Corradini","email":"","orcid":"https://orcid.org/0000-0002-9186-1353","institution":"Department of Oncology and Hemato-Oncology, University of Milan, Milan","correspondingAuthor":false,"prefix":"","firstName":"Paolo","middleName":"","lastName":"Corradini","suffix":""},{"id":316613740,"identity":"9af4f4ec-f8ad-4fdc-b8a3-5a574f67bb7f","order_by":25,"name":"Paolo Bernasconi","email":"","orcid":"","institution":"HSCT Unit, UOC Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia","correspondingAuthor":false,"prefix":"","firstName":"Paolo","middleName":"","lastName":"Bernasconi","suffix":""},{"id":316613741,"identity":"4164bf84-c85d-467c-b9b6-51bf660c335e","order_by":26,"name":"Anna Paola Iori","email":"","orcid":"","institution":"Policlinico Umberto 1","correspondingAuthor":false,"prefix":"","firstName":"Anna","middleName":"Paola","lastName":"Iori","suffix":""},{"id":316613742,"identity":"32d402cb-f023-48d8-9429-51de3b7c5310","order_by":27,"name":"Luca Castagna","email":"","orcid":"","institution":"UOSD Trapianto di Midollo, Ospedale Villa Sofia Cervello, Palermo","correspondingAuthor":false,"prefix":"","firstName":"Luca","middleName":"","lastName":"Castagna","suffix":""},{"id":316613743,"identity":"76c7b606-4858-44d6-8f13-b4ed96efe192","order_by":28,"name":"Nicola Mordini","email":"","orcid":"","institution":"Santa Croce e Carle Hospital, Division of Haematology, Cuneo","correspondingAuthor":false,"prefix":"","firstName":"Nicola","middleName":"","lastName":"Mordini","suffix":""},{"id":316613744,"identity":"f85a0f7b-2676-42b7-b893-e60b81c84975","order_by":29,"name":"Elena Oldani","email":"","orcid":"","institution":"ASST Papa Giovanni XXIII","correspondingAuthor":false,"prefix":"","firstName":"Elena","middleName":"","lastName":"Oldani","suffix":""},{"id":316613745,"identity":"8a822133-223b-42b9-83ae-ccfcdf4a6c98","order_by":30,"name":"Carmen DI Grazia","email":"","orcid":"","institution":"UO Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, Genova","correspondingAuthor":false,"prefix":"","firstName":"Carmen","middleName":"DI","lastName":"Grazia","suffix":""},{"id":316613746,"identity":"6845e185-57c4-4eff-8128-d8fb11e010cb","order_by":31,"name":"Andrea Bacigalupo","email":"","orcid":"","institution":"Fondazione Policlinico Universitario A. Gemelli IRCCS","correspondingAuthor":false,"prefix":"","firstName":"Andrea","middleName":"","lastName":"Bacigalupo","suffix":""}],"badges":[],"createdAt":"2024-06-17 15:11:39","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4595013/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4595013/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41408-024-01116-5","type":"published","date":"2024-08-21T04:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":60602305,"identity":"21cf0fcb-3036-4327-b0f5-505b9fbb9344","added_by":"auto","created_at":"2024-07-18 16:12:47","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":586954,"visible":true,"origin":"","legend":"\u003cp\u003eNon-relapse mortality at year 4 and 10 after transplantation of the entire study population (Panel A); Non-relapse mortality at 4 - and 10 years in patients younger than 51 years (Panel B); Non-relapse mortality at 4 - and 10 years in patients older than 51 years (Panel C).\u003c/p\u003e","description":"","filename":"Figure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4595013/v1/f1e846a15fe4aea7279ecc55.jpg"},{"id":60601246,"identity":"c13a0f0b-775b-4cf7-ac63-69cbcaf9a801","added_by":"auto","created_at":"2024-07-18 16:04:47","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":365943,"visible":true,"origin":"","legend":"\u003cp\u003eDeath events in patients older 51 years old in the first year after transplant\u003c/p\u003e","description":"","filename":"Figure2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4595013/v1/78497083876337faafa7c6ca.jpg"},{"id":60601245,"identity":"ebea8927-57c2-48d8-91bd-547d1b69a1ef","added_by":"auto","created_at":"2024-07-18 16:04:47","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":567458,"visible":true,"origin":"","legend":"\u003cp\u003eA) Cumulative incidence of relapse at 10 years in the entire study population; B) Cumulative incidence of relapse at 10 years in patients younger than 51 years; C) Cumulative incidence of relapse at 10 years in patients older than 51 years\u003c/p\u003e","description":"","filename":"Figure3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4595013/v1/cedaffad9c112e93de9fbdf9.jpg"},{"id":60602304,"identity":"91e03aab-517a-4064-a51b-5f90a9638a83","added_by":"auto","created_at":"2024-07-18 16:12:47","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":1103820,"visible":true,"origin":"","legend":"\u003cp\u003eLeukemia-free survival at 10 years in the entire study population (Panel A); Leukemia-free survival in patients younger than 51 (Panel B); Leukemia-free survival in patients older than 51(panel C); Overall survival at 10 years in the entire study population (Panel D); Overall survival in patients younger than 51 (Panel E); Overall survival in patients older than 51 (Panel F)\u003c/p\u003e","description":"","filename":"Figure4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4595013/v1/7dde2c54416a31e9e3b9d511.jpg"},{"id":63071639,"identity":"4153d5db-5f53-4817-9d75-dea87fb5fe6a","added_by":"auto","created_at":"2024-08-22 20:09:11","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":3384578,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4595013/v1/dade6809-e78c-47d6-9da1-af2e43655ed2.pdf"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e conflict of interest to disclose.","formattedTitle":"Busulfan-Fludarabine Versus Busulfan-Cyclophosphamide for Allogeneic Transplant in Acute Myeloid Leukemia: Long Term Analysis of GITMO AML-R2 Trial","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAcute myeloid leukemia (AML) currently represents the first indication of hematopoietic stem cell transplantation (HSCT)\u003csup\u003e1\u003c/sup\u003e, especially in intermediate and poor risk profile in first complete remission (CR)\u003csup\u003e2\u003c/sup\u003e. It represents the sole potentially curative treatment for relapsed/refractory disease\u003csup\u003e3\u003c/sup\u003e. For decades, the association between busulfan and cyclophosphamide (BuCy2) has been the standard of care conditioning regimen for HSCT in AML patients, showing favorable outcomes when compared to the combination of cyclophosphamide and total body irradiation (TBI)\u003csup\u003e4,5\u003c/sup\u003e. However, pivotal studies incorporating this regimen showed significant rates of non-relapse mortality (NRM) events, which make this therapy difficult to apply in patients older than 40 years old. Reduced-intensity conditioning regimens are associated with lower NRM, but this benefit could be offset by an increased incidence of relapse\u003csup\u003e6\u003c/sup\u003e. Therefore, new conditioning regimens were developed, to maintain antileukemic and myeloablative properties while reducing therapy-related toxicity, making it suitable also for older or comorbid AML patients. These are generally referred to as reduced toxicity myeloablative conditioning regimens. Among reduced toxicity regimens, the association of busulfan and fludarabine (BuFlu) represents a prototype\u003csup\u003e7\u003c/sup\u003e. Early experiences showed the efficacy of this combination in AML patients\u003csup\u003e8\u003c/sup\u003e, showing nonetheless conflicting data on disease relapse when compared to BuCy2 in non-randomized studies\u003csup\u003e9,10\u003c/sup\u003e. The AML-R2 trial was a phase 3 trial planned and conducted by the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) comparing busulfan-fludarabine (BuFlu) and busulfan-cyclophosphamide (BuCy2) as myeloablative conditioning regimens in acute myeloid leukemia (AML) patients undergoing allogeneic stem cell transplantation (Clinicaltrial.gov identifier: NCT01191957)\u003csup\u003e11\u003c/sup\u003e. The primary endpoint was 1-year non-relapse mortality (NRM), which proved significantly lower in BuFlu (7.9% vs. 17.2% in BuCy2 arm, p\u0026thinsp;=\u0026thinsp;0.026). There was no difference between the two arms in terms of cumulative incidence of relapse (CIR), leukemia free survival (LFS), overall survival (OS) at 1 and 2 years after transplant. Grade III-IV acute graft versus host disease (GvHD) was significantly higher in BuCy2 group (12 patients [10%]) than BuFlu group (3 patients [2%]). Hereby, we present the long-term follow-up analysis of this clinical trial and provide a sub-analysis on patients older than 51 years.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003ePatients\u0026rsquo; study population and trial design\u003c/h2\u003e \u003cp\u003eDetails concerning eligibility criteria and study treatments were reported in the original publication\u003csup\u003e11\u003c/sup\u003e. Briefly, patients were eligible if they were aged 40\u0026ndash;65 years, had an AML in first or second CR, had an Eastern Cooperative Oncology Group (ECOG) less than 3, had a sibling or matched unrelated donor with a molecular high-resolution typing of the HLA-A, B, C and DRB1 [One antigen/allele disparity (class I) or one allele disparity (class II, DRB1) was acceptable]. Key exclusion criteria were represented by AML with t(15;17) or PML/RARα positive acute promyelocytic leukemia, or AML with t(8;21)(q22;q22), inv(\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e) or t(16;16)(p13;q22) without additional adverse cytogenetic abnormalities; a previous HSCT; presence of comorbidities that would preclude the HSCT or the ability to provide truly informed consent; an active neoplasm or history of malignancies within 2 years before enrolment. both treatment groups received the same intravenous myeloablative dose of busulfan, 0.8 mg/kg four times per day for four consecutive days. In BuCy2 group, busulfan was combined with a standard dose of cyclophosphamide, 60 mg/kg per day for two consecutive days (on days \u0026minus;\u0026thinsp;4 and \u0026minus;\u0026thinsp;3, total dose 120 mg/kg); in BuFlu group, cyclophosphamide was replaced by fludarabine 40 mg/sqm per day for four consecutive days (from day \u0026minus;\u0026thinsp;6 through day \u0026minus;\u0026thinsp;3, total dose 160 mg/sqm). Transplant was performed on day 0, with patients receiving either bone marrow or granulocyte-colony stimulating agent (G-CSF) mobilized peripheral blood stem cells (PBSC). Graft-versus-host-disease (GvHD) prophylaxis was based on cyclosporine-A (1.5 mg/kg twice per day, starting from day \u0026minus;\u0026thinsp;1) and methotrexate (15 mg/sqm on day 1, 10 mg/sqm on days 3, 6, 11); in case of unrelated donors, anti-Thymocyte Globulin (ATG) was given at a total dose of 5 mg/kg (or 7.5 mg/kg in case of HLA acceptable disparity).\u003c/p\u003e \u003cp\u003eFor this long-term analysis, upon obtaining a written informed consent, we evaluated the long-term NRM, LFS, CIR, OS, chronic GvHD and relapse-free survival (GRFS) and the incidence of cGvHD of any grade. We also searched for long-term adverse events, especially second neoplasms, which were defined as invasive cancers, excluding basal cell and in situ skin cancers\u003csup\u003e12\u003c/sup\u003e. Outcomes were evaluated from the day of transplant in the intention-to-treat population, for the entire study population and then further stratified according to the median age (51 years). The choice of analyzing this subpopulation is based on the paucity of data from randomized trial concerning the use myeloablative conditioning regimen for AML transplantation in older adults. The study was approved by the Bergamo ethics committee.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eAll the clinical outcomes were calculated from transplant to the first event or the last follow-\u003c/p\u003e \u003cp\u003eup. Non-relapse mortality (NRM) was defined as death from any cause not subsequent to relapse. Overall survival (OS) was defined as the time from transplant to death from any cause. Leukemia-free survival (LFS) was defined as the time from transplant to disease relapse or death from any cause, whichever came first. Chronic GVHD-free and leukemia-free survival (GLFS) was defined as the time from transplant to disease relapse or chronic GVHD or death from any cause, whichever came first. Disease relapse was defined as hematological relapse (blast counts\u0026thinsp;\u0026gt;\u0026thinsp;5% in bone marrow). NRM, cumulative incidence of relapse (CIR) and chronic GvHD incidence were estimated using cumulative incidence function, considering relapse and death as a competing event for NRM and other incidence, respectively; the Gray\u0026rsquo;s non-parametric test was used to assess group differences. OS, LFS and GLFS were estimated using the Kaplan-Meier method and the log-rank test was applied to test differences between groups. Univariate analysis was performed by fitting Fine and Gray models for cumulative incidences and Cox models for survival outcomes. Hazard ratio with 95% confidence intervals were reported. A significance level of 0.05 was fixed. All the analysis were performed with R software (version 4.0.0).\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003eFrom January 3, 2008, to December 20, 2012, 252 AML patients with a median age of 51 years, were randomized 1:1 to BuCy2 (n\u0026thinsp;=\u0026thinsp;125) or BuFlu (n\u0026thinsp;=\u0026thinsp;127). Treatment was delivered in 121 patients in BuCy2 arm and 124 patients in BuFlu arm; baseline patients\u0026rsquo; characteristics are reported in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. The median follow-up for the study population was 6 years (range 0.03-13). The NRM for the entire study population remained significantly different up to 4 years after transplant (10% in BuFlu arm vs 20% in BuCy2 arm, p\u0026thinsp;=\u0026thinsp;0.0388). The NRM was not different for patients younger than 51 years (10% in BuFlu vs 14% in BuCy2, p\u0026thinsp;=\u0026thinsp;NS), but it was remarkably significant in patients older than 51 years (11% in BuFlu vs 27% in BuCy2, p\u0026thinsp;=\u0026thinsp;0.0262) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBaseline patients\u0026rsquo; and transplant characteristics\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCharacteristics\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAll\u003c/p\u003e \u003cp\u003en\u0026thinsp;=\u0026thinsp;252 (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBuFlu\u003c/p\u003e \u003cp\u003en\u0026thinsp;=\u0026thinsp;127 (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eBuCy2\u003c/p\u003e \u003cp\u003en\u0026thinsp;=\u0026thinsp;125 (%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003ep\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eAge, years\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emedian (range)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e50.8 (38\u0026ndash;65)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e51.1 (38\u0026ndash;65)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e50.5 (39\u0026ndash;65)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;51\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e128 (50.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e62 (48.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e66 (52.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;51\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e124 (49.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e65 (51.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e59 (47.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eSex\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003efemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e113 (44.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e57 (44.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e56 (44.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003emale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e139 (55.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e70 (55.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e69 (55.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eAML type\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ede novo\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e205 (81.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e103 (81.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e102 (81.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003esecondary\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e46 (18.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e24 (18.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e22 (17.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eunknown\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1 (0.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eDisease status at alloSCT\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u0026deg; CR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e213 (84.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e108 (85.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e105 (84)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026ge;\u0026thinsp;2\u0026deg; CR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e37 (14.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18 (14.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e19 (15.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eunknown\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eELN risk\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003egood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e27 (10.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13 (10.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e14 (11.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eintermediate-1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e123 (48.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e62 (48.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e61 (48.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eintermediate-2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e40 (15.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e17 (13.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e23 (18.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eadverse\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e55 (21.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e32 (25.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e23 (18.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eunknown\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e7 (2.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (2.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4 (3.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eDonor type\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003erelated\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e114 (45.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e58 (45.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e56 (44.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eunrelated\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e138 (54.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e69 (54.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e69 (55.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eGraft source\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ebone marrow\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e77 (30.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e36 (28.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e41 (32.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eperipheral blood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e168 (66.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e88 (69.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e80 (64.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eunknown\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e7 (2.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (2.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4 (3.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eDonor-recipient sex pair\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003efemale to male\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e42 (16.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23 (18.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e19 (15.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eothers\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e209 (82.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e104 (81.9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e105 (84.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eunknown\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1 (0.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eRecipient/donor CMV serology\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003enegative/negative\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e20 (8.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12 (9.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8 (6.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003enegative/positive\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e16 (6.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (4.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10 (8.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003epositive/negative\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e68 (27.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e37 (29.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e31 (24.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003epositive /positive\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e144 (57.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e69 (54.3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e75 (60.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eunknown\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e4 (1.6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (2.4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (0.8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ens\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eMoreover, patients older than 51 years in the BuCy2 arm, had an incidence of non-relapse death of 23% in the first year after transplant, with infections being the first cause of death (14.3%), even more than disease relapse (10.7%); on the contrary, in this population, non-relapse death in BuFlu arm was 9.5% in the first year. Death events in the first year after transplant for patients older than 51 years are summarized in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003ePatients older than 51 years receiving BuFlu also experienced fewer organ-specific toxicities, which are early-onset adverse events strictly related to the conditioning regimen itself. As shown in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e, patients receiving BuCy2 had a higher number of any grade toxic event, especially grade 2\u0026ndash;3 (27 events in BuCy arms vs 17 events in the BuFlu arm).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eConditioning-related toxicities in the first month after transplant in patients older than 51 years\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c4\" namest=\"c2\"\u003e \u003cp\u003eBuCy2 (n\u0026thinsp;=\u0026thinsp;58)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c7\" namest=\"c5\"\u003e \u003cp\u003eBuFlu (n\u0026thinsp;=\u0026thinsp;63)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003eGrade 1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003eGrade 2\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003eGrade 3\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003eGrade 1\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003eGrade 2\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003eGrade 3\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eMucosa\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e13 (22%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e7 (11%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e12 (19%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLiver\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4 (7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eGut\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e6 (10%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eBladder\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eHeart\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eKidney\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eCNS\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLung\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1 (2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eWe observed 46 relapses in the BuCy2 arm and 53 in the BuFlu arm, with most relapses diagnosed in the first 2 years after transplant; 8% of relapses occurred later than 5 after transplant (3 in the BuCy2 arm, 5 in the BuFlu arm).\u003c/p\u003e \u003cp\u003eThe CIR was not statistically different in both arms (39% vs 37% in BuFlu vs. BuCy2 arm, Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e). Similarly, we did not observe any difference in LFS (45% vs 38% in BuFlu and BuCy2 arms, respectively) and OS (45% in both arms); curves are shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eWe also did not observe a difference in cumulative incidence of moderate/severe cGvHD (15% in the BuFlu arm vs 22% in the BuCy2 arm) and GRFS in the BuFlu arm vs the BuCy2 arm (25% vs 20% at 4 years; 20% vs 17% at 10 years, respectively).\u003c/p\u003e \u003cp\u003eDuring the entire available follow-up, we observed a total of 137 deaths, 66 in BuCy2 arm and 71 in the BuFlu arm. Disease relapse was the main cause of death, occurring in 88 patients (37 in the BuCy2 arm vs 51 in the BuFlu arm), while non-relapse events leading to death occurred in 49 patients (29 in Bucy2 arm vs 20 in BuFlu arm). In the original trial, NRM events were 36, 23 in BuCy2 arm and 13 in BuFlu arm (p\u0026thinsp;=\u0026thinsp;0.060). Long-term analysis showed 13 new NRM events, 5 in BuCy2 arm (2 for second neoplasm, 2 for infection, 1 for other unspecified reason) and 8 in BuFlu arm (5 for second neoplasm, 2 for infection, 1 for cardiovascular disease). Among the 13 deceased patients, 6 had a concomitant moderate/severe cGvHD. Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e summarizes all death events occurring along the entire available follow-up.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eDeath events along the entire available post-transplant follow-up\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003e13 years post transplant\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBuCy2 (n\u0026thinsp;=\u0026thinsp;125)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBuFlu (n\u0026thinsp;=\u0026thinsp;127)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eTOTAL MORTALITY\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003e66 (52.8%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e71 (55.9%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eRelapse death\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003e37 (29.6%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e51 (40.2%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eNon relapse death\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003e29 (23.2%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e20 (15.7%)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eInfection\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e16 (55%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8 (40%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePneumonia\u003c/p\u003e \u003cp\u003eBacterial / Viral / Fungal / Unknown\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e9\u003c/p\u003e \u003cp\u003e3 / 1 / 1 / 3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003cp\u003e1 / 2 / 1 / 2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEncephalitis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUnspecified infection\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAcute GvHD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5 (17%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (15%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSecond neoplasms\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5 (25%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCardiac toxicity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2 (10%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eGastrointestinal toxicity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHemorrhage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (5%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOther\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (5%)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eWe detected a total of 19 second neoplasms, 6 in BuCy2 arm and 13 in BuFlu arm; in 7 cases, the second tumor was the cause of death (n\u0026thinsp;=\u0026thinsp;5 in BuFlu arm, n\u0026thinsp;=\u0026thinsp;2 in BuCy2 arm).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe AML-R2 study planned and conducted by the GITMO group showed a reduction in NRM in BuFlu compared to the BuCy2 arm, with no detrimental effects on disease relapse. This long-term analysis was aimed to confirm and further evaluate these findings throughout the available follow-up. We showed that the benefit of NRM reduction is sustained up to 4 years after transplant and the incidence of late relapses does not offset this advantage. Moreover, NRM continues to be halved in BuFlu arm, as it was initially hypothesized and proved in the clinical trial 1 year after the transplant. NRM proved lower in BuFlu arm even 10 years after transplant but, due to the occurrence of late non-relapse death in BuFlu arm, (infections and second neoplasms above all) the statistical significance is lost. Our data are in line with the analysis led by Fasslrinner et al., who analyzed the long-term outcomes of the randomized trial comparing two TBI-containing conditioning regimens in HSCT for AML, and showed that NRM at 10 years was not significantly different between the two study arms\u003csup\u003e13\u003c/sup\u003e. Indeed, many registry analyses with follow-up close to 10 years showed that patients undergoing HSCT have an increased risk of death compared to the general age-matched population for the sole reason of having received an HSCT, independently of the type of conditioning regimen and the disease for which the patient was transplanted\u003csup\u003e14\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe performed sub-analysis on patients older than 51 showed that the global benefit of BuFlu is due to NRM reduction in this specific population. Randomized data on myeloablative conditioning in patients above 51 years are rather sparse. Indeed, most of the available clinical data on myeloablative conditioning come from non-randomized studies in younger patients. Our analysis shows the feasibility of the myeloablative BuFlu regimen even in adults older than 51, with a NRM similar to younger patients and an acceptable safety profile. Our results also confirm that the myeloablative BuFlu program allows an optimal balance between anti-leukemic activity and toxicity\u003csup\u003e15\u003c/sup\u003e, with NRM comparable to those reported by recently published randomized trials comparing reduced intensity conditioning regimens\u003csup\u003e16,17\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eA recent retrospective analysis of the Acute Leukemia Working Party of the European Society of Bone Marrow Transplant (EBMT) compared outcomes of a myeloablative combination of treosulfan and fludarabine (FT14) with BuFlu in patients with AML stratified per age older or younger than 55 years. With the limitation of a retrospective analysis and a relatively short follow-up, the FT14 conditioning was associated with a greater incidence of relapse and shorter LFS in patients younger than 55, while all the other outcomes were similar in patients older than 55. Limiting the analysis on patients receiving BuFlu, 2-year NRM was 7.7% and CIR was 27.5%\u003csup\u003e18\u003c/sup\u003e. Another recent publication of the Acute Leukemia Working Party of the EBMT retrospectively compared BuFlu with the myeloablative regimen based on TBI 12 Gy and fludarabine showing no difference between these two conditioning regimens, with a 2-year NRM and CIR in BuFlu arm of 10.9% and 29.4%, respectively\u003csup\u003e19\u003c/sup\u003e. Collectively, these findings from an International Registry demonstrate that real-life outcomes with BuFlu are basically superimposable to the ones observed in the clinical trial.\u003c/p\u003e \u003cp\u003eA very recent randomized phase 3 trial from the Chinese group compared BuFlu and BuCy2 in the haploidentical setting. The 1-year NRM was 7.2% in BuFlu vs 14.1% in BuCy2, whereas the 5-year relapse incidence was 17.9% and 14.2% respectively. This study showed that outcomes with BuFlu are independent of the donor type and the subsequently adopted GvHD prophylaxis. Moreover, authors found a reduced incidence of grade 3 regimen-related toxicities (0% in BuFlu vs 9% in BuCy2), thus confirming that BuFlu is less toxic when compared to BuCy2, even in patients receiving post-transplant cyclophosphamide\u003csup\u003e20\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe long-term analysis of the AML-R2 trial showed that disease relapse nearly reaches 40% in both arms, with most relapses occurring within the first two years, in line with other reports\u003csup\u003e13,21\u003c/sup\u003e. This finding allows some considerations: first, the prolonged reduction in NRM is not offset by increased disease relapse and this is sustained even at a very long follow-up. In addition, disease relapse remains the leading cause of death in both arms and up to 8% of relapses occur later than 5 years after transplant, meaning that the treating physician should always be aware of the risk of the relapse, even at a very long follow-up, and in case of suspect, disease relapse must be thoroughly investigated. Finally, the risk definition according to the ELN classification was not associated with a major impact on late relapses. It has to be noted that, when the trial was conducted, post-transplant therapies (e.g., FLT3 inhibitors) were not available and this might have had a role in the high incidence of relapse we observed in both arms. Innovative post-transplant therapies are urgently needed.\u003c/p\u003e \u003cp\u003eWe observed a non-significant increase in relapse death in the BuFlu arm (53 relapses with 51 deaths) with regards to the BuCy2 arm (46 relapses and 39 deaths). This finding was already outlined in the original clinical trial publication and potentially linked to a deeper immunosuppressive microenvironment. However, the number of relapses does not allow us to draw a definitive conclusion, and mechanisms underlying late relapses are probably much more complex and likely unrelated to the conditioning regimen. Nonetheless, most patients who relapsed either after BuFlu or BuCy2, unfortunately died. It is therefore confirmed that the probability of prolonged leukemia control when transplant fails after myeloablative conditioning remains very limited.\u003c/p\u003e \u003cp\u003eThe combination of late non-relapse and relapse-associated deaths in the BuFlu arm explains the absence of any meaningful difference in the OS observed in the two randomized arms.\u003c/p\u003e \u003cp\u003eConcerning long-term toxicities, we focused on second neoplasms, whose incidence was 8%. The incidence of secondary neoplasms in the entire cohort is in line with data showing a progressive rise when an appropriate long-term follow-up analysis is conducted\u003csup\u003e22\u003c/sup\u003e. We observed a slight increase in second neoplasm incidence in BuFlu arm, although the absolute number of events is too low to reach a statistical significance. The deeper immunosuppressive activity of fludarabine could be also related to this late development of a second neoplasm. Nonetheless, cancerogenesis is a complex process in which many other transplant-related features could play a role, mainly cGvHD with all the related immunosuppressive therapy. In addition, retrospective studies did not find any difference between RIC and MAC regimens with the development\u003csup\u003e23,24\u003c/sup\u003e of secondary neoplasms, further suggesting that the type of conditioning on second neoplasms is not straightforward.\u003c/p\u003e \u003cp\u003eThis long-term analysis has some limitations. First, these long-term follow-up data were collected retrospectively and were merged with data from the clinical trial, which were collected prospectively. Second, this long-term analysis was not pre-planned, so information concerning long-term follow-up has been collected according to the local clinical practice of the participating centers. Finally, the clinical trial was not designed to identify differences according to the median age of the study population.\u003c/p\u003e \u003cp\u003eNonetheless, we confirmed a sustained reduction in NRM when the myeloablative BuFlu is used as a conditioning regimen in adult AML. Based on these long-term results from a randomized multicentre study, we believe that this preparative regimen should be considered as a standard of care conditioning regimen for AML patients undergoing HSCT, even in the haploidentical setting. The possibility to use this conditioning regimen can be extended to a selected group of AML patients older than 51 years, for whom a myeloablative regimen could provide a more active anti-leukemic effect\u003csup\u003e6,25\u003c/sup\u003e. For these patients, BuFlu is associated with a reduction in early conditioning-related organ toxicities.\u003c/p\u003e \u003cp\u003eSince the low NRM has been confirmed after a long-term follow-up, this offers the possibility to plan effective innovative post-transplant therapies to tackle the risk of disease relapse, which remains the major unmet clinical need after transplantation.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003e\u003cu\u003eCompeting interests\u003c/u\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAuthors declare no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cu\u003eAcknowledgment\u003c/u\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was in part supported with grants by the Associazione Italiana per la Ricerca sul Cancro (AIRC) and the Associazione Italiana Lotta alla Leucemia (Sezione Paolo Belli, Bergamo, Italy). We thank all physicians and nursing staff of GITMO Centers for the clinical care of patients enrolled in this study, and the data manager for data acquisition.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cu\u003eAuthors\u0026rsquo; Contribution\u003c/u\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConception and design\u003c/strong\u003e: Alessandro Rambaldi designed the clinical trial.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eProvision of study materials or patients\u003c/strong\u003e: Gianluca Cavallaro, Anna Grassi, Maria Caterina Mic\u0026ograve;, Alessandro Busca, Irene Maria Cavattoni, Stella Santarone, Carlo Borghero, Attilio Olivieri, Giuseppe Milone, Patrizia Chiusolo, Pellegrino Musto, Riccardo Saccardi, Francesca Patriarca, Fabrizio Pane, Giorgia Saporiti, Paolo Rivela, Elisabetta Terruzzi, Raffaella Cerretti, Giuseppe Marotta, Angelo Michele Carella, Arnon Nagler, Domenico Russo, Paolo Corradini, Paolo Bernasconi, Anna Paola Iori, Luca Castagna, Nicola Mordini, Elena Oldani, Carmen Di Grazia, Andrea Bacigalupo, Alessandro Rambaldi\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCollection and assembly of data\u003c/strong\u003e: Gianluca Cavallaro, Anna Grassi, Chiara Pavoni\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData analysis and interpretation\u003c/strong\u003e: Chiara Pavoni, Gianluca Cavallaro, Anna Grassi, Alessandro Rambaldi\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eManuscript writing\u003c/strong\u003e: All authors\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinal approval of manuscript\u003c/strong\u003e: All authors\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAccountable for all aspects of the work\u003c/strong\u003e: All authors\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eD\u0026rsquo;Souza A, Fretham C, Lee SJ, et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. \u003cem\u003eBiol Blood Marrow Transplant\u003c/em\u003e. 2020;26(8):e177-e182\u003c/li\u003e\n\u003cli\u003eCornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. \u003cem\u003eBlood\u003c/em\u003e. 2016;127(1):62-70\u003c/li\u003e\n\u003cli\u003eHeinicke T, Krahl R, Kahl C, et al. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. \u003cem\u003eAnn Hematol\u003c/em\u003e. 2021;100(9):2387-2398\u003c/li\u003e\n\u003cli\u003eNagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: Comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus cy as conditioning regimen-A report from the acute leukemia workin. \u003cem\u003eJ Clin Oncol\u003c/em\u003e. 2013;31(28):3549-3556\u003c/li\u003e\n\u003cli\u003eCopelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. \u003cem\u003eBlood\u003c/em\u003e. 2013;122(24):3863-3870\u003c/li\u003e\n\u003cli\u003eScott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. \u003cem\u003eJ Clin Oncol\u003c/em\u003e. 2017;35(11):1154-1161\u003c/li\u003e\n\u003cli\u003eDe Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. \u003cem\u003eBlood\u003c/em\u003e. 2004;104(3):857-864\u003c/li\u003e\n\u003cli\u003eAndersson BS, de Lima M, Thall PF, et al. Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS. \u003cem\u003eBiol Blood Marrow Transplant\u003c/em\u003e. 2008;14(6):672-684\u003c/li\u003e\n\u003cli\u003eChae YS, Sohn SK, Kim JG, et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: Comparison with BuCy2. \u003cem\u003eBone Marrow Transplant\u003c/em\u003e. 2007;40(6):541-547\u003c/li\u003e\n\u003cli\u003eBredeson CN, Zhang MJ, Agovi MA, et al. Outcomes following HSCT Using Fludarabine, Busulfan, and Thymoglobulin: A Matched Comparison to Allogeneic Transplants Conditioned with Busulfan and Cyclophosphamide. \u003cem\u003eBiol Blood Marrow Transplant\u003c/em\u003e. 2008;14(9):993-1003\u003c/li\u003e\n\u003cli\u003eRambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial. \u003cem\u003eLancet Oncol\u003c/em\u003e. 2015;16(15):1525-1536\u003c/li\u003e\n\u003cli\u003eRizzo JD, Curtis RE, Sobocinski KA, et al. Solid cancers after allogeneic hematopoietic cell transplantation. 2009;113(5):1175-1183\u003c/li\u003e\n\u003cli\u003eFasslrinner F, Schetelig J, Burchert A, et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase . \u003cem\u003eLancet Haematol\u003c/em\u003e. 2018;5(4):e161-e169\u003c/li\u003e\n\u003cli\u003eMajhail NS. Long-term complications after hematopoietic cell transplantation. \u003cem\u003eHematol Oncol Stem Cell Ther\u003c/em\u003e. 2017;10(4):220-227\u003c/li\u003e\n\u003cli\u003eLiu H, Zhai X, Song Z, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: A prospective and multicen. \u003cem\u003eJ Hematol Oncol\u003c/em\u003e. 2013;6(1):1-9\u003c/li\u003e\n\u003cli\u003eCraddock C, Jackson A, Loke J, et al. Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. \u003cem\u003eJ Clin Oncol\u003c/em\u003e. 2021;39(7):768-778\u003c/li\u003e\n\u003cli\u003eBeelen DW, Trenschel R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 . \u003cem\u003eLancet Haematol\u003c/em\u003e. 2020;7(1):e28-e39\u003c/li\u003e\n\u003cli\u003eGavriilaki E, Labopin M, Sakellari I, et al. Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia. \u003cem\u003eBone Marrow Transplant\u003c/em\u003e. 2022;(October 2021):1-7.\u003c/li\u003e\n\u003cli\u003eSwoboda R, Labopin M, Giebel S, et al. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par. \u003cem\u003eBone Marrow Transplant\u003c/em\u003e. 2023;58(3):282-287\u003c/li\u003e\n\u003cli\u003eLing Y, Xuan L, Xu N, et al. Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. \u003cem\u003eJ Clin Oncol\u003c/em\u003e 2023:1-12\u003c/li\u003e\n\u003cli\u003eWingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. \u003cem\u003eJ Clin Oncol\u003c/em\u003e. 2011;29(16):2230-2239\u003c/li\u003e\n\u003cli\u003eMajhail NS, Brazauskas R, Douglas Rizzo J, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. \u003cem\u003eBlood\u003c/em\u003e. 2011;117(1):316-322\u003c/li\u003e\n\u003cli\u003eRingd\u0026eacute;n O, Brazauskas R, Wang Z, et al. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. \u003cem\u003eBiol Blood Marrow Transplant\u003c/em\u003e. 2014;20(11):1777-1784\u003c/li\u003e\n\u003cli\u003eShimoni A, Shem-Tov N, Chetrit A, et al. Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; The incidence is not reduced. \u003cem\u003eLeukemia\u003c/em\u003e. 2013;27(4):829-835\u003c/li\u003e\n\u003cli\u003eScott BL, Pasquini MC, Fei M, et al. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes\u0026mdash;Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial: \u003cem\u003eTransplant Cell Ther\u003c/em\u003e. 2021;27(6):483.e1-483.e6. \u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"blood-cancer-journal","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"bcj","sideBox":"Learn more about [Blood Cancer Journal](http://www.nature.com/bcj/)","snPcode":"41408","submissionUrl":"https://mts-bcj.nature.com/cgi-bin/main.plex","title":"Blood Cancer Journal","twitterHandle":"@bloodcancerjnl","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-4595013/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4595013/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eWe report the long-term results of a randomized trial (GITMO, AML-R2), comparing 1:1 the combination of busulfan and cyclophosphamide (BuCy2, n= 125) and the combination of busulfan and fludarabine (BuFlu, n= 127) as conditioning regimen in acute myeloid leukemia patients (median age 51 years, range 40-65) undergoing allogeneic hematopoietic stem cell transplantation. With a median follow-up of 6 years, significantly better non-relapse mortality (NRM) was confirmed in BuFlu recipients, which is sustained up to 4 years after transplant (10% vs 20%, p= 0.0388). This difference was higher in patients older than 51 years (11 % in BuFlu vs 27% in BuCy2, p= 0.0262). The cumulative incidence of relapse, which was the first cause of death in the entire study population, did not differ between the two randomized arms. Similarly, the leukemia-free survival (LFS) and overall survival (OS) were not different in the two cohorts, even when stratifying patients per median age. Graft-and relapse free-survival (GRFS) in BuFlu arm vs the BuCy2 arm was 25% vs 20% at 4 years and 20% vs 17% at 10 years. Hence, the benefit gained by NRM reduction is not offsets by an increased relapse. Leukemia relapse remains a major concern, urging the development of new therapeutic approaches.\u003c/p\u003e","manuscriptTitle":"Busulfan-Fludarabine Versus Busulfan-Cyclophosphamide for Allogeneic Transplant in Acute Myeloid Leukemia: Long Term Analysis of GITMO AML-R2 Trial","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-07-18 16:04:42","doi":"10.21203/rs.3.rs-4595013/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"revise","date":"2024-07-05T10:12:20+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"This content is not available.","date":"2024-06-26T07:56:27+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2024-06-20T05:13:20+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewersInvited","content":"","date":"2024-06-20T00:41:24+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-06-19T10:36:17+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-06-19T10:36:09+00:00","index":"","fulltext":""},{"type":"submitted","content":"Blood Cancer Journal","date":"2024-06-18T15:27:19+00:00","index":"","fulltext":""},{"type":"checksFailed","content":"","date":"2024-06-18T10:23:16+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"blood-cancer-journal","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"bcj","sideBox":"Learn more about [Blood Cancer Journal](http://www.nature.com/bcj/)","snPcode":"41408","submissionUrl":"https://mts-bcj.nature.com/cgi-bin/main.plex","title":"Blood Cancer Journal","twitterHandle":"@bloodcancerjnl","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"4de276f5-f75f-40e1-8427-fa8a3153b673","owner":[],"postedDate":"July 18th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":33480318,"name":"Health sciences/Medical research/Clinical trial design/Randomized controlled trials"},{"id":33480319,"name":"Health sciences/Medical research/Clinical trial design/Clinical trials/Phase III trials"}],"tags":[],"updatedAt":"2024-08-22T19:47:47+00:00","versionOfRecord":{"articleIdentity":"rs-4595013","link":"https://doi.org/10.1038/s41408-024-01116-5","journal":{"identity":"blood-cancer-journal","isVorOnly":false,"title":"Blood Cancer Journal"},"publishedOn":"2024-08-21 04:00:00","publishedOnDateReadable":"August 21st, 2024"},"versionCreatedAt":"2024-07-18 16:04:42","video":"","vorDoi":"10.1038/s41408-024-01116-5","vorDoiUrl":"https://doi.org/10.1038/s41408-024-01116-5","workflowStages":[]},"version":"v1","identity":"rs-4595013","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4595013","identity":"rs-4595013","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}